Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019

Journal of Biomedical Nanotechnology

Volumn 10, Issue 5, 2014, Pages 877-884

  Heffeter, P ^a   Riabtseva, A ^b   Senkiv, Y ^a,c   Kowol, C R ^d   Korner W ^d   Jungwith, U ^a   Mitina, N ^b   Keppler, B K ^d   Konstantinova, T ^e   Yanchuk, I ^f   Stoika, R ^c   Zaichenko, A ^b   Berger, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LVIV POLYTECHNIC NATIONAL UNIVERSITY   (Ukraine)

^c INSTITUTE OF CELL BIOLOGY   (Ukraine)

^d UNIVERSITY OF VIENNA   (Austria)

^e DONETSK PHYSICOTECHNICAL INSTITUTE   (Ukraine)

^f NANOMEDTECH LLC   (Ukraine)

Author keywords

Anticancer cancer therapy; Cell death induction; Drug delivery; Nanocarrier; Ruthenium

Indexed keywords

CELL DEATH; DRUG DELIVERY; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; RUTHENIUM; SOLUTIONS;

APOPTOTIC CELL DEATH; CANCER THERAPY; CLINICAL APPLICATION; CLINICAL EVALUATION; ENHANCED STABILITY; NANOCARRIERS; NANOPARTICLE FORMULATION; RUTHENIUM COMPLEXES;

RUTHENIUM COMPOUNDS;

ANTINEOPLASTIC AGENT; CASPASE 7; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYMER; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; BIOACCUMULATION; CELL DEATH; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG STABILITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; M PHASE CELL CYCLE CHECKPOINT; MICELLE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIFFUSION; DRUG COMPOUNDING; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INDAZOLES; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; TREATMENT OUTCOME;

EID: 84897134683     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1763     Document Type: Article

References (14)

1. P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L. Elbling, M. Micksche, B. Keppler, and W. Berger, Resistance against novel anticancer metal compounds: Differences and similarities. Drug. Resist. Updat. 11, 1 (2008).
2. C. G. Hartinger, S. Zorbas-Seifried, M. A. Jakupec, B. Kynast, H. Zorbas, and B. K. Keppler, From bench to bedsid-e-preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H- indazole)ruthenate (III)] (KP1019 or FFC14A). J. Inorg. Biochem. 100, 891 (2006).
3. V. P. Torchilin, Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol. Life Sci. 61, 2549 (2004).
4. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov, Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug. Deliv. Rev. 54, 759 (2002).
5. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, Nanonization Copyright: American strategies for poorly water-soluble drugs. Drug. Discov. Today 16, 354 (2011).
6. B. Cebrian-Losantos, E. Reisner, C. R. Kowol, A. Roller, S. Shova, V. B. Arion, and B. K. Keppler, Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru (III)Cl4(indazole)2]. Inorg. Chem. 47, 6513 (2008).
7. P. Heffeter, K. Bock, B. Atil, M. A. Reza Hoda, W. Korner, C. Bartel, U. Jungwirth, B. K. Keppler, M. Micksche, W. Berger, and G. Koellensperger, Intracellular protein binding patterns of the anti-cancer ruthenium drugs KP1019 and KP1339, J. Biol. Inorg. Chem. 15, 737 (2010).
8. S. Kapitza, M. A. Jakupec, M. Uhl, B. K. Keppler, and B. Marian, The heterocyclic ruthenium (III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer. Lett. 226, 115 (2005).
9. A. Riabtseva, N. Mitina, N. Boiko, S. Garasevich, I. Yanchuk, R. Stoika, O. Slobodyanyuk, and A. Zaichenko, Structural and colloidal-chemical characteristics of nanosized drug delivery systems based on PEGylated comb-like carriers. Chemistry and Chemical Technology 6, 291 (2012).
10. K. G. Lipponer, E. Vogel, and B. K. Keppler, Synthesis, characterization and solution chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate (III), a new Anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. crystal structures of trans-1-Methyl- Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate (III) and its Hydrolysis Product trans-Monoaquatrichlorobis-(1-Methylindazole)-Ruthenate (III). Metal-Based Drugs 3, 243 (1996).
11. A. Egger, C. Rappel, M. A. Jakupec, C. G. Hartinger, P. Heffeter, and B. K. Keppler, Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J. Anal. At. Spectrom. 24, 51 (2009).
12. C. R. Kowol, P. Heffeter, W. Miklos, L. Gille, R. Trondl, L. Cappellacci, W. Berger, and B. K. Keppler, Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. J. Biol. Inorg. Chem. (2011).
13. P. Heffeter, A. Popovic-Bijelic, P. Saiko, R. Dornetshuber, U. Jungwirth, N. Voevodskaya, D. Biglino, M. A. Jakupec, L. Elbling, M. Micksche, T. Szekeres, B. K. Keppler, A. Graslund, and W. Berger, Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum (III)] trithiocyanate (KP772). Curr. Cancer Drug Targets 9, 595 (2009).
14. R. R. Tice, E. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi, Y. Miyamae, E. Rojas, J. C. Ryu, and Y. F. Sasaki, Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35, 206 (2000).